Efficacy and safety profile comparison of colistin and tigecycline on the extensively drug resistant Acinetobacter baumannii

Biological and Pharmaceutical Bulletin

Volumn 37, Issue 3, 2014, Pages 340-346

  Kwon, Sung Hee ^a   Ahn, Hye Lim ^a   Han, Ok Yeon ^a   La, Hyen O ^a,b  

^a The Catholic University of Korea   (South Korea)

^b The Catholic University of Korea   (South Korea)

Author keywords

Acinetobacter baumannii; Colistin; Extensively drug resistant (XDR); Tigecycline

Indexed keywords

ALANINE AMINOTRANSFERASE; ALKALINE PHOSPHATASE; AMIKACIN; AMYLASE; ASPARTATE AMINOTRANSFERASE; AZTREONAM; BILIRUBIN; CEFEPIME; CEFTAZIDIME; CEPHALOSPORIN DERIVATIVE; CIPROFLOXACIN; COLISTIMETHATE; COLISTIN; COTRIMOXAZOLE; CREATININE; GENTAMICIN; IMIPENEM; LEVOFLOXACIN; MEROPENEM; MINOCYCLINE; NITROGEN; PIPERACILLIN; PIPERACILLIN PLUS TAZOBACTAM; SULTAMICILLIN; TICARCILLIN; TIGECYCLINE; TIMENTIN; TOBRAMYCIN; UNINDEXED DRUG; UREA;

ABDOMINAL PAIN; ACINETOBACTER BAUMANNII; ACINETOBACTER INFECTION; ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALKALINE PHOSPHATASE BLOOD LEVEL; ANTIBIOTIC SENSITIVITY; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BLOOD TOXICITY; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DIARRHEA; DRUG EFFICACY; DRUG SAFETY; DRUG TREATMENT FAILURE; ELECTROLYTE DISTURBANCE; EXTENSIVELY DRUG RESISTANT ACINETOBACTER INFECTION; FEMALE; FEVER; HEMATOLOGIC MALIGNANCY; HUMAN; HYPOALBUMINEMIA; INTENSIVE CARE; INTERNATIONAL NORMALIZED RATIO; LENGTH OF STAY; LIVER TOXICITY; MAJOR CLINICAL STUDY; MALE; MORTALITY; MULTIDRUG RESISTANCE; NAUSEA AND VOMITING; NEPHROTOXICITY; NEUROLOGIC DISEASE; NONHUMAN; OBSERVATIONAL STUDY; PARTIAL THROMBOPLASTIN TIME; PNEUMONIA; PROGNOSIS; PROTHROMBIN TIME; PRURITUS; RASH; RETROSPECTIVE STUDY; SEPSIS; SOLID TUMOR; TREATMENT DURATION; UNSPECIFIED SIDE EFFECT; UREA NITROGEN BLOOD LEVEL; URTICARIA;

ACINETOBACTER BAUMANNII; ACINETOBACTER INFECTIONS; ADMINISTRATION, INTRAVENOUS; ADULT; AGED; ANTI-BACTERIAL AGENTS; COLISTIN; CREATININE; DRUG RESISTANCE, MULTIPLE, BACTERIAL; FEMALE; HUMANS; INTENSIVE CARE UNITS; KIDNEY; LENGTH OF STAY; MALE; MIDDLE AGED; MINOCYCLINE; RETROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 84896944078     PISSN: 09186158     EISSN: 13475215     Source Type: Journal    
DOI: 10.1248/bpb.b13-00109     Document Type: Article

References (27)

1. Towner KJ. Acinetobacter: an old friend, but a new enemy. J. Hosp. Infect., 73, 355-363 (2009).
2. Vila J, Pachón J. Therapeutic Options for Acinetobacter baumannii Infections. Expert Opin. Pharmacother., 9, 587-599 (2008).
3. Corbella X, Montero A, Pujol M, Domínguez MA, Ayats J, Argerich MJ, Garrigosa F, Ariza J, Gudiol F. Emergence and rapid spread of carbapenem resistance during a large and sustained hospital outbreak of multiresistant Acinetobacter baumannii. J. Clin. Microbiol., 38, 4086-4095 (2000).
4. Isabel Dueñas Díez A, Angel Bratos Pérez M, María Eiros Bouza J, Almaraz Gómez A, Gutiérrez Rodríguez P, Antonia Miguel Gómez M, Orduña Domingo A, Rodríguez-Torres A. Susceptibility of the Acinetobacter calcoaceticus - A. baumannii complex to imipenem, meropenem, sulbactam and colistin. Int. J. Antimicrob. Agents, 23, 487-493 (2004).
5. Kumazawa J, Yagisawa M. The History of Antibiotics: The Japanese Story. J. Infect. Chemother., 8, 125-133 (2002).
6. Kucers A, Crowe S, Grayson ML, Hoy JF. The use of antibiotics. 5th ed., Heinemann, London, p. 899 (1997).
7. Michalopoulos AS, Tsiodras S, Rellos K, Mentzelopoulos S, Falagas ME. Colistin treatment in patients with ICU-acquired infections caused by multiresistant Gram-negative bacteria: the renaissance of an old antibiotic. Clin. Microbiol. Infect., 11, 115-121 (2005).
8. Chan JD, Graves JA, Dellit TH. Antimicrobial treatment and clinical outcomes of carbapenem-resistant Acinetobacter baumannii ventilator-associated pneumonia. J. Intensive Care Med., 25, 343-348 (2010).
9. Karageorgopoulos DE, Kelesidis T, Kelesidis I, Falagas ME. Tigecycline for the treatment of multidrug-resistant (including carbapenem-resistant) Acinetobacter infections: a review of the scientific evidence. J. Antimicrob. Chemother., 62, 45-55 (2008).
10. Manchanda V, Shinha S, Singh NP. Multidrug resistant Acinetobacter. J. Glob. Infect. Dis., 2, 291-304 (2010).
11. Gaynes R, Edwards JR. Overview of Nosocomial Infections Caused by Gram-Negative Bacilli. Clin. Infect. Dis., 41, 848-854 (2005).
12. Sunenshine RH, Wright MO, Maragakis LL, Harris AD, Song X, Hebden J, Cosgrove SE, Anderson A, Carnell J, Jernigan DB, Kleinbaum DG, Perl TM, Standiford HC, Srinivasan A. Multidrug-resistant Acinetobacter infection mortality rate and length of hospitalization. Emerg. Infect. Dis., 13, 97-103 (2007).
13. Paterson DL. The Epidemiological Profile of Infections with Multidrug-Resistant Pseudomonas aeruginosa and Acinetobacter Species. Clin. Infect. Dis., 43 (Suppl. 2), S43-S48 (2006).
14. Playford EG, Craig JC, Iredell JR. Carbapenem-resistant Acinetobacter baumannii in intensive care unit patients: risk factors for acquisition, infection and their consequences. J. Hosp. Infect., 65, 204-211 (2007).
15. Manikal VM, Landman D, Saurina G, Oydna E, Lal H, Quale J. Endemic carbapenem-resistant Acinetobacter species in Brooklyn, New York: citywide prevalence, interinstitutional spread, and relation to antibiotic usage. Clin. Infect. Dis., 31, 101-106 (2000).
16. Peleg AY, Franklin C, Bell JM, Spelman DW. Emergence of carbapenem resistance in Acinetobacter baumannii recovered from blood cultures in Australia. Infect. Control Hosp. Epidemiol., 27, 759-761 (2006).
17. Falagas ME, Bliziotis IA, Siempos II. Attributable mortality of Acinetobacter baumannii infections in critically ill patients: a systematic review of matched cohort and case-control studies. Crit. Care, 10, R48 (2006).
18. Maragakis LL, Perl TM. Acinetobacter baumannii: epidemiology, antimicrobial resistance, and treatment options. Clin. Infect. Dis., 46, 1254-1263 (2008).
19. Garnacho-Montero J, Amaya-Villar R. Multiresistant Acinetobacter baumannii Infections: Epidemiology and Management. Curr. Opin. Infect. Dis., 23, 332-339 (2010).
20. Levin AS, Barone AA, Penço J, Santos MV, Marinho IS, Arruda EA, Manrique EI, Costa SF. Intravenous Colistin as Therapy for Nosocomial Infections Caused by Multidrug-Resistant Pseudomonas aeruginosa and Acinetobacter baumannii. Clin. Infect. Dis., 28, 1008-1011 (1999).
21. Korbila IP, Michalopoulos A, Rafailidis PI, Nikita D, Samonis G, Falagas ME. Inhaled colistin as adjunctive therapy to intravenous colistin for the treatment of microbiologically documented ventilator-associated pneumonia: a comparative cohort study. Clin. Microbiol. Infect., 16, 1230-1236 (2010).
22. Gordon NC, Wareham DW. A review of clinical and microbiological outcomes following treatment of infections involving multidrug-resistant Acinetobacter baumannii with tigecycline. J. Antimicrob. Chemother., 63, 775-780 (2009).
23. Giamarellou H. Multidrug-resistant Gram-negative bacteria: how to treat and for how long. Int. J. Antimicrob. Agents, 36 (Suppl. 2), S50-S54 (2010).
24. Falagas ME, Kasiakou SK. Colistin: the revival of polymyxins for the management of multidrug-resistant Gram-negative bacterial infections. Clin. Infect. Dis., 40, 1333-1341 (2005).
25. Kallel H, Hergafi L, Bahloul M, Hakim A, Dammak H, Chelly H, Hamida CB, Chaari A, Rekik N, Bouaziz M. Safety and efficacy of colistin compared with imipenem in the treatment of ventilator-associated pneumonia: a matched case-control study. Intensive Care Med., 33, 1162-1167 (2007).
26. Koch-Weser J, Sidel VW, Federman EB, Kanarek P, Finer DC, Eaton AE. Adverse effects of sodium colistimethate. Manifestations and specific reaction rates during 317 courses of therapy. Ann. Intern. Med., 72, 857-868 (1970).
27. Reed MD, Stern RC, O'Riordan MA, Blumer JL. The pharmacokinetics of colistin in patients with cystic fibrosis. J. Clin. Pharmacol., 41, 645-654 (2001).